UK biotech company Cytospire Therapeutics has closed a £61 million ($83 million) Series A financing round to advance T cell engagers, 4BIO Capital has announced. The venture capital firm led the financing round, with proceeds allowing Cytospire to advance its pipeline of first-in-class pan-gamma delta T cell engagers. The company’s lead programme, CYT X300, is currently being advanced through IND-enabling […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!